The antineoplastic activity of the thioredoxin reductase 1 (TrxR) inhibitor, auranofin (AF), has
already been investigated in various cancer mouse models as a single drug, or in …

Background The orally available gold complex auranofin (AF) has been used in humans,
primarily as an antirheumatic/immunomodulatory agent. It has been safely administered to …

Anticancer drugs that target cellular antioxidant systems have recently attracted much
attention. Auranofin (AF) is currently evaluated in several clinical trials as an anticancer …

Gold compounds have a long history of use in medicine. Auranofin was developed more
than 30 years ago as an oral therapy for rheumatoid arthritis. Now, however, auranofin is …

Auranofin, as a thioredoxin reductase (TrxR) inhibitor, has promising anti-cancer activity in
several cancer types. However, little is known about the inhibitory effect of auranofin on lung …

Gold compounds have been employed throughout history to treat various types of disease,
from ancient times to the present day. In the year 1985, auranofin, a gold-containing …

Auranofin is an oral gold (I) compound, initially developed for the treatment of rheumatoid
arthritis. Currently, Auranofin is under investigation for oncological application within a drug …

Auranofin, an inhibitor of thioredoxin reductase (TrxR), inhibits the growth of a variety of
cancer cells. In the present study, various lung cancer cells were used to investigate the …

Auranofin (AF) is an anti-arthritic drug considered for combined chemotherapy due to its
ability to impair the redox homeostasis in tumor cells. In this study, we asked whether AF …

The cytosolic thioredoxin redox system composed of thioredoxin-1 and the NADPH-
dependent thioredoxin reductase-1 reductase is an important regulator of cell growth and …